Isatuximab monotherapy or combination therapy with dexamethasone in older adult patients with relapsed/refractory multiple myeloma: a single institution experience

被引：0
|
作者：
Iino, Masaki [1 ]
Mikawa, Takahiro [1 ]
Kido, Shinji [1 ]
Fujimori, Ken [1 ]
机构：
[1] Yamanashi Prefectural Cent Hosp, Yamanashi, Japan
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-273
引用
收藏
页码：S186 / S186
页数：1
相关论文
共 50 条
  • [41] Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma
    Fenk, Roland
    Michael, Mark
    Zohren, Fabian
    Graef, Thorsten
    Czibere, Akos
    Bruns, Ingmar
    Neumann, Frank
    Fenk, Barbara
    Haas, Rainer
    Kobbe, Guido
    LEUKEMIA & LYMPHOMA, 2007, 48 (12) : 2345 - 2351
  • [42] Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma
    Castelli, Roberto
    Pantaleo, Giuseppe
    Gallipoli, Paolo
    Gidaro, Antonio
    Arquati, Massimo
    Wu, Maddalena A.
    Deliliers, Giorgio Lambertenghi
    ANTI-CANCER DRUGS, 2015, 26 (10) : 1078 - 1082
  • [43] Salvage Therapy with Bortezomib and Dexamethasone in Elderly Patients with Relapsed Refractory Multiple Myeloma
    Castelli, Roberto
    Gallipoli, Paolo
    Gidaro, Antonio
    Maddalena, Wu
    Arquati, Massimo
    Deliliers, Giorgio Lambertenghi
    BLOOD, 2015, 126 (23)
  • [44] Thalidomide in relapsed or refractory patients with multiple myeloma: Monotherapy or combination therapy? A report from systematic reviews.
    Glasmacher, A
    Hahn, C
    Hoffmann, F
    Furkert, K
    von Lilienfeld-Toal, M
    Orlopp, K
    Naumann, R
    Goldschmidt, H
    Schmidt-Wolf, IGH
    Gorschlueter, M
    BLOOD, 2005, 106 (11) : 364B - 364B
  • [45] Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results
    Vij, Ravi
    Huff, Carol Ann
    Bensinger, William I.
    Siegel, David S.
    Jagannath, Sundar
    Berdeja, Jesus
    Lendvai, Nikoletta
    Lebovic, Daniel
    Anderson, Larry D.
    Costello, Caitlin L.
    Stockerl-Goldstein, Keith E.
    Laubach, Jacob P.
    Elias, Laurence
    Clow, Fong
    Fardis, Maria
    Graef, Thorsten
    Bilotti, Elizabeth
    Richardson, Paul G.
    BLOOD, 2014, 124 (21)
  • [46] Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma
    Atieh, Tahani
    Atrash, Shebli
    Ahmed, Nausheen
    Mohan, Meera
    Cui, Wei
    Shune, Leyla
    Hajjar, Susana
    Mahmoudjafari, Zahra
    Quick, Julie
    Wishna, Anne
    Riffel, Justin
    McGuirk, Joseph
    Mohyuddin, Ghulam Rehman
    Abdallah, Al-Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (12): : 912 - 919
  • [47] Venetoclax Monotherapy and Combined with Dexamethasone as Targeted Therapy for Relapsed/Refractory t(11;14) Multiple Myeloma
    Kaufman, J.
    Gasparetto, C.
    Mikhael, J.
    Moreau, P.
    Touzeau, C.
    Vij, R.
    Facon, T.
    Pegourie, B.
    Benboubker, L.
    Boise, L.
    Hong, W. J.
    Jiang, Y.
    Alzate, S.
    Dunbar, M.
    Pesko, J.
    Friese, K.
    Ross, J.
    Maciag, P.
    Kumar, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 182 - 183
  • [48] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Song Mu
    Yoshiaki Kuroda
    Hirohiko Shibayama
    Masayuki Hino
    Takeshi Tajima
    Claudia Corrado
    Rong Lin
    Edward Waldron
    Florence Binlich
    Kenshi Suzuki
    European Journal of Clinical Pharmacology, 2016, 72 : 153 - 161
  • [49] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Mu, Song
    Kuroda, Yoshiaki
    Shibayama, Hirohiko
    Hino, Masayuki
    Tajima, Takeshi
    Corrado, Claudia
    Lin, Rong
    Waldron, Edward
    Binlich, Florence
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 153 - 161
  • [50] EFFICACY OF THE COMBINATION THERAPY OF LIPOSOMAL ADRYAMICIN, BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ABCD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
    Romano, A.
    Chiarenza, A.
    Gorgone, A.
    Schinocca, L.
    Uccello, G.
    Cavalli, M.
    Fiumara, P.
    Motta, G.
    Palumbo, G.
    Di Raimondo, F.
    HAEMATOLOGICA, 2012, 97 : 607 - 607
12345